Emodin Inhibits breast cancer growth by blocking the tumor-promoting feedforward loop between cancer cells and macrophages

Molecular Cancer Therapeutics

Volumn 15, Issue 8, 2016, Pages 1931-1942

  Iwanowycz, Stephen ^a   Wang, Junfeng ^a   Hodge, Johnie ^a   Wang, Yuzhen ^a   Yu, Fang ^a,b   Fan, Daping ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; EMODIN; HISTONE H3; INTERFERON REGULATORY FACTOR 4; STAT6 PROTEIN; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL ADHESION; CELL INFILTRATION; CELL SURFACE; CELL VIABILITY; CHINESE HERB; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TUMOR CELL CULTURE; TUMOR IMMUNITY; TUMOR PROMOTION; TUMOR VOLUME; ANIMAL; BREAST NEOPLASMS; CELL COMMUNICATION; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ANIMALS; BIOMARKERS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; T-LYMPHOCYTE SUBSETS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84986268767     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0987     Document Type: Article

References (50)

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2013;64:52-62.
2. Rudnick JA, Kuperwasser C. Stromal biomarkers in breast cancer development and progression. Clin Exp Metastasis 2012;29:663-72.
3. Schouppe E, De Baetselier P, Van Ginderachter JA, Sarukhan A. Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations. Oncoimmunology 2012;1:1135-45.
4. Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett 2016;370:85-90.
5. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015;33:2092-9.
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
7. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014; 111:11774-9.
8. Singh M, Ramos I, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, et al. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triplenegative breast cancer model 4T1. Cancer Med 2013;2:571-82.
9. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
10. Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012;12:306.
11. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009; 284:34342-54.
12. Lu H, Clauser KR, Tam WL, Frose J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol 2014;16:1105-17.
13. Pignatelli J, Goswami S, Jones JG, Rohan TE, Pieri E, Chen X, et al. Invasive breast carcinoma cells from patients exhibit MenaINV- and macrophagedependent transendothelial migration. Sci Signal 2014;7:ra112.
14. Su S, Liu Q, Chen J, Chen F, He C, Huang D, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 2014;25:605-20.
15. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013;2:e26968.
16. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 2014;515:130-3.
17. Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, et al. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer. Cancer Lett 2013;341: 139-49.
18. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev 2007;27:591-608.
19. Wei WT, Lin SZ, Liu DL, Wang ZH. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). Oncol Rep 2013;30:2555-62.
20. Li J, Liu P, Mao H, Wanga A, Zhang X. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 2009;21:1605-10.
21. Lin SZ, Wei WT, Chen H, Chen KJ, Tong HF, Wang ZH, et al. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS One 2012;7:e42146.
22. Jia X, Iwanowycz S, Wang J, Saaoud F, Yu F, Wang Y, et al. Emodin attenuates systemic and liver inflammation inhyperlipidemic mice administrated with lipopolysaccharides. Exp Biol Med (Maywood) 2014;239: 1025-35.
23. Zhu S, Wang Y, Wang X, Li J, Hu F. Emodin inhibits ATP-induced IL-1beta secretion, ROS production and phagocytosis attenuation in rat peritoneal macrophages via antagonizing P2X(7) receptor. Pharm Biol 2014;52:51-7.
24. Jia X, Yu F, Wang J, Iwanowycz S, Saaoud F, Wang Y, et al. Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat 2014;148:291-302.
25. Casey AE, Laster WRJr., Ross GL. Sustained enhanced growth of carcinoma EO771 in C57 black mice. Proc Soc Exp Biol Med 1951;77:358-62.
26. Nachat-Kappes R, Pinel A, Combe K, Lamas B, Farges MC, Rossary A, et al. Effects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancer. PLoS One 2012;7:e51525.
27. Incio J, Tam J, Rahbari NN, Suboj P, McManus DT, Chin SM, et al. PlGF/ VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clin Cancer Res 2016 Feb 9. [Epub ahead of print].
28. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23:249-62.
29. Wang J, Yu F, Jia X, Iwanowycz S, Wang Y, Huang S, et al. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer 2015;136:602-13.
30. El ChartouniC,Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiology 2010;215:821-5.
31. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010;11:936-44.
32. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9.
33. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014;105:1-8.
34. Adiseshaiah PP, Patel NL, Ileva LV, Kalen JD, Haines DC, McNeil SE. Longitudinal imaging of cancer cell metastases in two preclinical models: a correlation of noninvasive imaging to histopathology. Int J Mol Imaging 2014;2014:102702.
35. DuPre SA, Redelman D, Hunter KWJr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 2007;88:351-60.
36. Wang B, Chen L, Sun Y, Zhu Y, Sun Z, An T, et al. Development of phenylboronic acid-functionalized nanoparticles for emodin delivery. J Mater Chem B Mater Biol Med 2015;3:3840-7.
37. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm 2012;430:238-46.
38. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, et al. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007;6:987-94.
39. Sandholt IS, Olsen BB, Guerra B, Issinger OG. Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 2009;20:238-48.
40. Zheng Y, Qin H, Frank SJ, Deng L, Litchfield DW, Tefferi A, et al. A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 2011;118:156-66.
41. Singh KB, Trigun SK. Apoptosis of Dalton's lymphoma due to in vivo treatment with emodin is associated with modulations of hydrogen peroxide metabolizing antioxidant enzymes. Cell Biochem Biophys 2013; 67:439-49.
42. Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res 2013;23: 898-914.
43. Damodharan U, Ganesan R, Radhakrishnan UC. Expression of MMP2 and MMP9 (gelatinases A and B) in human colon cancer cells. Appl Biochem Biotechnol 2011;165:1245-52.
44. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, et al. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 2006;118: 2711-20.
45. Kaneshiro T, Morioka T, Inamine M, Kinjo T, Arakaki J, Chiba I, et al. Anthraquinone derivative emodin inhibits tumor-associated angiogenesis through inhibition of extracellular signal-regulated kinase 1/2 phosphorylation. Eur J Pharmacol 2006;553:46-53.
46. Kumar A, Dhawan S, Aggarwal BB. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene 1998;17:913-8.
47. Liu C. Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin. Mol Med Rep 2015;11:4087-92.
48. Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B. Tumors escape CD4+ T-cell-mediated immunosurveillance by impairing the ability of infiltrating macrophages to indirectly present tumor antigens. Cancer Res 2015;75:3268-78.
49. Long KB, Beatty GL. Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology 2013;2:e26860.
50. Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy 2013;5:1075-87.